Library — CHDR

Search

Filter

Towards a sustainable system of drug development.

Moors EH, Cohen AF, Schellekens H

Drug discovery today, 2014 Oct; 19(11):1711-20

View publication
Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.

Brill MJ, van Rongen A, Houwink AP, Burggraaf J, van Ramshorst B, Wiezer RJ, van Dongen EP, Knibbe CA

Clinical pharmacokinetics, 2014 Sep; 53(10):931-41

View publication
[Practical guideline for the use of colistin].

Dijkmans AC, Wilms EB, Kamerling IM, Birkhoff W, van Nieuwkoop C, Verbrugh HA, Touw DJ

Nederlands tijdschrift voor geneeskunde, 2014 Sep

View publication
Prehospital use in emergency patients of a laryngeal mask airway by ambulance paramedics is a safe and effective alternative for endotracheal intubation.

Bosch J, de Nooij J, de Visser M, Cannegieter SC, Terpstra NJ, Heringhaus C, Burggraaf J

Emergency medicine journal : EMJ, 2014 Aug; 31(9):750-3

View publication
Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant.

Hoch M, van Gorsel H, van Gerven J, Dingemanse J

Journal of clinical pharmacology, 2014 Aug; 54(9):979-86

View publication
Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.

Diamant Z, Sidharta PN, Singh D, O'Connor BJ, Zuiker R, Leaker BR, Silkey M, Dingemanse J

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2014 Aug; 44(8):1044-52

View publication
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.

Cruz HG, Hay JL, Hoever P, Alessi F, te Beek ET, van Gerven JM, Dingemanse J

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014 Jul; 24(8):1257-68

View publication
Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.

De Kam PJ, Kruithof AC, van Lierop MJ, Moerland M, Dennie J, Troyer MD, Langdon RB, Gutstein DE, Burggraaf J, El Galta R

International journal of clinical pharmacology and therapeutics, 2014 Jul; 52(8):631-41

View publication
New EU clinical trials regulation.

Westra AE, Bos W, Cohen AF

BMJ (Clinical research ed.), 2014 Jun

View publication

«
1
2
...
51
52
53
54
55
56
57
...
98
99
»